NCT05088460: A reported trial by Regeneron Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05088460 |
|---|---|
| Title | A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients With Familial Partial Lipodystrophy |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 28, 2022 |
| Completion date | Dec. 13, 2023 |
| Required reporting date | Dec. 13, 2026, midnight |
| Actual reporting date | April 16, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |